Boron Neutron Capture Therapy of Brain Tumors: Investigation of Urinary Metabolites and Oxidation Products of Sodium Borocaptate by Electrospray Ionization Mass Spectrometry
Boron neutron capture therapy (BNCT) is based on a nuclear capture reaction that occurs when boron-10, a stable isotope, is irradiated with low energy neutrons to produce high-energy alpha particles and recoiling lithium-7 nuclei. The purpose of the present study was to determine what urinary metabo...
Saved in:
Published in | Drug metabolism and disposition Vol. 29; no. 12; pp. 1588 - 1598 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Bethesda, MD
American Society for Pharmacology and Experimental Therapeutics
01.12.2001
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Boron neutron capture therapy (BNCT) is based on a nuclear capture reaction that occurs when boron-10, a stable isotope, is
irradiated with low energy neutrons to produce high-energy alpha particles and recoiling lithium-7 nuclei. The purpose of
the present study was to determine what urinary metabolites, if any, could be detected in patients with brain tumors who were
given sodium borocaptate (BSH), a drug that has been used clinically for BNCT. BSH was infused intravenously over a 1-h time
period at doses of 26.5, 44.1, or 88.2 mg/kg of body weight to patients with high-grade brain tumors. Electrospray ionization
mass spectrometry has been used to investigate possible urinary metabolites of BSH. Chemical and instrument conditions were
established to detect BSH and its possible metabolites in both positive and negative electrospray ionization modes. Using
this methodology, boronated ions were found in patients' urine samples that appeared to be consistent with the following chemical
structures: BSH sulfenic acid (BSOH), BSH sulfinic acid (BSO 2 H), BSH disulfide (BSSB), BSH thiosulfinate (BSOSB), and a BSH- S -cysteine conjugate (BSH-CYS). Although BSH has been used clinically for BNCT since the late 1960s, this is the first report
of specific biotransformation products following administration to patients. Further studies will be required to determine
both the biological significance of these metabolites and whether any of these accumulate in significant amounts in brain
tumors. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0090-9556 1521-009X |